Amphastar Director Sells 16,679 Shares for $441,800

Floyd Petersen, manager of Amphastar Pharmaceuticals (NASDAQ:AMPH), exercised 16,679 options for communal banal and instantly sold each resulting shares successful a transaction valued astatine $441,836.72, arsenic disclosed successful a SEC Form 4 filing.

Transaction worth based connected SEC Form 4 weighted mean acquisition terms ($26.49); post-transaction worth based connected Nov. 13, 2025 marketplace adjacent ($26.37).

• How does the size of this transaction comparison to Petersen's humanities selling activity?
  The merchantability of 16,679 shares connected November 13, 2025, is materially larger than the humanities median sell-only transaction of 500 shares.

• What is the derivative discourse of this transaction?
  All 16,679 shares sold originated from the workout of afloat vested banal options, with contiguous disposition successful the unfastened market.

• How does the transaction worth subordinate to Petersen Floyd F.'s remaining nonstop ownership?
  Following the sale, Petersen Floyd F. retains 75,531 shares with an approximate marketplace worth of $2.0 cardinal arsenic of November 13, 2025, reflecting a 4% simplification successful nonstop holdings since May 2024.

• What was the marketplace discourse astatine the clip of the sale?
  Shares were priced astatine astir $26.49 per stock for the transaction, with the banal closing astatine $26.37 connected November 13, 2025. Over the anterior 12 months, the banal declined by 42% arsenic of the transaction date.

* 1-year show is calculated utilizing November 13th, 2025 arsenic the notation date.

• Offers a diversified portfolio of injectable, inhalation, and intranasal pharmaceutical products, including Primatene Mist, Enoxaparin, Naloxone, Glucagon, and specialty APIs.

• Generates gross done the development, manufacturing, and merchantability of some generic and proprietary drugs, with a absorption connected specialty and emergency-use medications.

• Serves hospitals, attraction facilities, alternate attraction sites, clinics, and physicians, chiefly targeting the U.S. China, and France markets.

Amphastar Pharmaceuticals, Inc. is simply a mid-cap biopharmaceutical institution specializing successful specialty and generic injectable and inhalation products. The institution leverages a vertically integrated model, with in-house API accumulation and a divers merchandise pipeline, to code captious needs successful acute attraction and exigency medicine. Its strategical absorption connected some proprietary and generic products positions it to seizure request from organization healthcare providers and respond to evolving marketplace opportunities.